Publications by authors named "L Corrales"
Article Synopsis
- The CheckMate-743 trial showed that nivolumab plus ipilimumab improves overall survival in patients with unresectable pleural mesothelioma compared to chemotherapy, but lacked representation of Latin American patients.
- A retrospective study evaluated this treatment's effectiveness and safety in 96 LATAM patients, focusing on their demographic and clinical characteristics, with a median follow-up of 24.1 months.
- Results indicated median progression-free survival of 8 months and overall survival of 22 months, confirming treatment benefits similar to other findings, with manageable adverse events reported.
Agricultural Biotechnological Potential of Bacillus velezensis C3-3 and Cytobacillus sp. T106 from Resource Islands of a Semi-arid Zone of La Guajira-Colombia.
Curr Microbiol
September 2024
Resource islands are vegetative formations in arid and semi-arid ecosystems that harbor microorganisms facing extreme conditions. However, there is a limitation in the knowledge of the agricultural biotechnological potential of microorganisms present in these islands. This study aimed to determine the capacity of Bacillus velezensis C3-3 and Cytobacillus sp.
View Article and Find Full Text PDFArticle Synopsis
- Latin American populations exhibit a rich genetic diversity due to the mixing of European, Native American, Asian, and African ancestries, leading to unique genetic variants that challenge traditional population genetics methods.
- This genetic diversity significantly impacts health, particularly in cancer, as varying genetic ancestries and lifestyle factors contribute to different cancer incidence and mortality rates among subpopulations.
- Studies reveal that specific genetic variants related to breast, lung, colorectal, and prostate cancers are more prevalent in these populations, indicating the need for tailored approaches to cancer treatment and prognostic assessments.
Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor mutant (EGFRm) advanced non-small cell lung cancer (NSCLC). Combining TKIs with an angiogenesis inhibitor has shown promise in pre-clinical studies. A systematic search of clinical trials found that combining erlotinib (a first-generation TKI) with bevacizumab or ramucirumab (angiogenesis inhibitors) improved progression-free survival (PFS) in EGFRm advanced NSCLC patients compared to TKI alone.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the safety of using taxane-based chemotherapy for breast cancer during pregnancy, focusing on the risks for both mothers and newborns.
- It involved 103 patients, primarily treated with paclitaxel and anthracyclines, with a median taxane initiation at 28 weeks of gestation.
- Results showed a low incidence of severe adverse events, with a high live birth rate and generally favorable obstetric outcomes, supporting the use of taxanes during pregnancy when necessary.